Adam D. Durbin

3.4k total citations · 1 hit paper
38 papers, 1.6k citations indexed

About

Adam D. Durbin is a scholar working on Molecular Biology, Neurology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Adam D. Durbin has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 18 papers in Neurology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Adam D. Durbin's work include Neuroblastoma Research and Treatments (17 papers), Protein Degradation and Inhibitors (11 papers) and Sarcoma Diagnosis and Treatment (10 papers). Adam D. Durbin is often cited by papers focused on Neuroblastoma Research and Treatments (17 papers), Protein Degradation and Inhibitors (11 papers) and Sarcoma Diagnosis and Treatment (10 papers). Adam D. Durbin collaborates with scholars based in United States, Canada and United Kingdom. Adam D. Durbin's co-authors include A. Thomas Look, Brian J. Abraham, Richard A. Young, Avrum I. Gotlieb, David Malkin, Mark W. Zimmerman, Lee N. Lawton, Takaomi Sanda, Alla Berezovskaya and Alejandro Gutiérrez and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Angewandte Chemie International Edition.

In The Last Decade

Adam D. Durbin

37 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

2014 538 citations Marc R. Mansour, Brian J. Abraham et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adam D. Durbin United States	18	1.1k	374	348	228	186	38	1.6k
Naotoshi Kanda Japan	19	1.0k 0.9×	306 0.8×	678 1.9×	296 1.3×	91 0.5×	40	1.7k
Graeme W. McLean United States	11	813 0.7×	163 0.4×	180 0.5×	284 1.2×	107 0.6×	11	1.5k
Margaret E. Macy United States	19	521 0.5×	149 0.4×	329 0.9×	385 1.7×	256 1.4×	57	1.3k
Shigeki Yagyu Japan	20	713 0.6×	294 0.8×	164 0.5×	656 2.9×	218 1.2×	67	1.4k
Laurence Blavier United States	17	830 0.7×	757 2.0×	164 0.5×	779 3.4×	95 0.5×	21	1.7k
H.-J. Terpe Germany	21	679 0.6×	189 0.5×	156 0.4×	486 2.1×	225 1.2×	34	1.4k
Charles D. Bangs United States	19	605 0.5×	145 0.4×	138 0.4×	580 2.5×	264 1.4×	44	1.6k
Sabrina Martín United States	17	409 0.4×	63 0.2×	111 0.3×	257 1.1×	148 0.8×	33	1.2k
Magdalena J. Glogowska United States	14	499 0.4×	95 0.3×	310 0.9×	187 0.8×	123 0.7×	15	1.4k
Inga Vater Germany	21	594 0.5×	304 0.8×	243 0.7×	377 1.7×	97 0.5×	35	1.6k

Countries citing papers authored by Adam D. Durbin

Since Specialization

Citations

This map shows the geographic impact of Adam D. Durbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam D. Durbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam D. Durbin more than expected).

Fields of papers citing papers by Adam D. Durbin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam D. Durbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam D. Durbin. The network helps show where Adam D. Durbin may publish in the future.

Co-authorship network of co-authors of Adam D. Durbin

This figure shows the co-authorship network connecting the top 25 collaborators of Adam D. Durbin. A scholar is included among the top collaborators of Adam D. Durbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam D. Durbin. Adam D. Durbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Song, Yan, Logan H. Sigua, Paul M.C. Park, et al.. (2026). Proteasome Cap Targeting Chimeras for Ubiquitination‐Independent Targeted Protein Degradation. Angewandte Chemie International Edition. 65(9). e20039–e20039.

Prutsch, Nicole, Shuning He, Alla Berezovskaya, et al.. (2024). STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. Cell Reports Medicine. 5(3). 101472–101472. 4 indexed citations

Ritter, Kristina & Adam D. Durbin. (2024). Lineage-Selective Dependencies in Pediatric Cancers. Cold Spring Harbor Perspectives in Medicine. 15(4). a041573–a041573. 2 indexed citations

Durbin, Adam D. & Rogier Versteeg. (2024). Cell state plasticity in neuroblastoma. SHILAP Revista de lepidopterología. 4. 100184–100184. 4 indexed citations

Delahunty, Ian, Gisele Nishiguchi, Yang Zhang, et al.. (2023). Abstract 481: Investigating molecular glues as a new therapeutic approach to high-risk neuroblastoma. Cancer Research. 83(7_Supplement). 481–481. 1 indexed citations

Zhang, Yuxiang, David Remillard, Joshua N. Asiaban, et al.. (2023). Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities. Nature Structural & Molecular Biology. 30(8). 1160–1171. 15 indexed citations

Weichert‐Leahey, Nina, Hui Shi, Ting Tao, et al.. (2023). Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state. Journal of Clinical Investigation. 133(10). 8 indexed citations

Zimmerman, Mark W., Nina Weichert‐Leahey, Belamy B. Cheung, et al.. (2021). MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. Cancers. 13(19). 4783–4783. 9 indexed citations

Wang, Lu, Tze King Tan, Adam D. Durbin, et al.. (2019). ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nature Communications. 10(1). 5622–5622. 54 indexed citations

10.

Ki, Dong Hyuk, Felix Oppel, Adam D. Durbin, & A. Thomas Look. (2019). Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Oncogene. 38(39). 6585–6598. 11 indexed citations

11.

Durbin, Adam D., Mark W. Zimmerman, Neekesh V. Dharia, et al.. (2018). Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nature Genetics. 50(9). 1240–1246. 145 indexed citations

12.

Zimmerman, Mark W., Yu Liu, Shuning He, et al.. (2018). c-MYC drives a subset of high-risk pediatric neuroblastomas and is activated through mechanisms including enhancer hijacking and focal enhancer amplification. PMC. 2 indexed citations

13.

Zimmerman, Mark W., Yu Liu, Shuning He, et al.. (2017). MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification. Cancer Discovery. 8(3). 320–335. 147 indexed citations

14.

Durbin, Adam D., Dong Hyuk Ki, Shuning He, & A. Thomas Look. (2016). Malignant Peripheral Nerve Sheath Tumors. Advances in experimental medicine and biology. 916. 495–530. 18 indexed citations

15.

Mansour, Marc R., Brian J. Abraham, Lars Anders, et al.. (2014). An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 346(6215). 1373–1377. 538 indexed citations breakdown →

16.

Pašić, Ivan, Adam Shlien, Adam D. Durbin, et al.. (2010). Recurrent Focal Copy-Number Changes and Loss of Heterozygosity Implicate Two Noncoding RNAs and One Tumor Suppressor Gene at Chromosome 3q13.31 in Osteosarcoma. Cancer Research. 70(1). 160–171. 126 indexed citations

17.

Greenberg, Joshua, Stig Sømme, Hege Russnes, Adam D. Durbin, & David Malkin. (2008). The Estrogen Receptor Pathway in Rhabdomyosarcoma: A Role for Estrogen Receptor-β in Proliferation and Response to the Antiestrogen 4′OH-Tamoxifen. Cancer Research. 68(9). 3476–3485. 18 indexed citations

18.

Makawita, Shalini, Michael Ho, Adam D. Durbin, et al.. (2008). Expression of Insulin-Like Growth Factor Pathway Proteins in Rhabdomyosarcoma: IGF-2 Expression is Associated with Translocation-Negative Tumors. Pediatric and Developmental Pathology. 12(2). 127–135. 32 indexed citations

19.

Strahm, Brigitte, et al.. (2007). The CXCR4-SDF1α axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clinical & Experimental Metastasis. 25(1). 1–10. 27 indexed citations

20.

Durbin, Adam D. & Avrum I. Gotlieb. (2002). Advances towards understanding heart valve response to injury. Cardiovascular Pathology. 11(2). 69–77. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact